Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NAKA KindlyMD	$11.02 -3.6%	$0.00	$0.65 ▼ $34.77	$66.45M	35.16	374,361 shs	246,966 shs
TOI Oncology Institute	$3.50 -4.1%	$2.74	$0.13 ▼ $3.78	$312.31M	0.02	1.23 million shs	2.67 million shs
VMD Viemed Healthcare	$6.49 -2.7%	$6.76	$6.14 ▼ $9.81	$256.49M	1.37	146,624 shs	206,271 shs
XGN Exagen	$7.00 -2.5%	$6.84	$1.78 ▼ $7.95	$149.10M	1.58	146,440 shs	145,690 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NAKA KindlyMD	0.00%	-10.41%	-22.50%	+1,101,999,900.00%	+1,101,999,900.00%
TOI Oncology Institute	0.00%	+11.82%	+46.44%	+46.44%	+567.94%
VMD Viemed Healthcare	0.00%	-3.71%	-1.96%	-1.82%	-4.70%
XGN Exagen	0.00%	+0.14%	-3.18%	+58.01%	+257.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NAKA KindlyMD	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TOI Oncology Institute	2.267 of 5 stars	3.8	2.0	0.0	0.0	3.1	0.8	0.0
VMD Viemed Healthcare	0.9574 of 5 stars	0.0	2.0	0.0	0.0	0.6	3.3	1.3
XGN Exagen	2.6749 of 5 stars	1.5	2.0	0.0	4.5	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NAKA KindlyMD	0.00	N/A	N/A	N/A
TOI Oncology Institute	3.50	Strong Buy	$6.50	85.71% Upside
VMD Viemed Healthcare	0.00	N/A	N/A	N/A
XGN Exagen	3.00	Buy	$7.50	7.14% Upside

Current Analyst Ratings Breakdown

Latest NAKA, TOI, VMD, and XGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	TOI Oncology Institute	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
7/15/2025	TOI Oncology Institute	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	XGN Exagen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/15/2025	TOI Oncology Institute	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00
5/15/2025	XGN Exagen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$8.00 ➝ $7.00
5/13/2025	XGN Exagen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/7/2025	XGN Exagen	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NAKA KindlyMD	$2.72M	24.43	N/A	N/A	$0.43 per share	25.63
TOI Oncology Institute	$393.41M	0.79	N/A	N/A	$0.05 per share	70.00
VMD Viemed Healthcare	$224.26M	1.14	$0.94 per share	6.90	$3.41 per share	1.90
XGN Exagen	$55.64M	2.68	N/A	N/A	$0.54 per share	12.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NAKA KindlyMD	-$3.62M	-$0.77	N/A	∞	N/A	-177.01%	-146.26%	-109.19%	N/A
TOI Oncology Institute	-$64.66M	-$0.70	N/A	∞	N/A	-15.38%	-445.02%	-34.13%	8/12/2025 (Estimated)
VMD Viemed Healthcare	$11.27M	$0.30	21.63	∞	N/A	5.28%	9.49%	7.14%	8/6/2025 (Estimated)
XGN Exagen	-$15.11M	-$0.84	N/A	N/A	N/A	-27.34%	-133.69%	-34.87%	7/29/2025 (Estimated)

Latest NAKA, TOI, VMD, and XGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	TOI Oncology Institute	-$0.13	N/A	N/A	N/A	$112.56 million	N/A
7/29/2025	Q2 2025	XGN Exagen	-$0.18	N/A	N/A	N/A	$16.25 million	N/A
5/14/2025	Q1 2025	TOI Oncology Institute	N/A	-$0.18	N/A	-$0.21	N/A	$104.41 million
5/12/2025	Q1 2025	XGN Exagen	-$0.20	-$0.20	N/A	-$0.20	$14.55 million	$15.50 million
5/7/2025	Q1 2025	VMD Viemed Healthcare	$0.06	$0.06	N/A	$0.06	$60.60 million	$59.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NAKA KindlyMD	N/A	N/A	N/A	N/A	N/A
TOI Oncology Institute	N/A	N/A	N/A	N/A	N/A
VMD Viemed Healthcare	N/A	N/A	N/A	N/A	N/A
XGN Exagen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NAKA KindlyMD	N/A	2.30	2.30
TOI Oncology Institute	14.58	1.79	1.59
VMD Viemed Healthcare	0.03	1.38	1.26
XGN Exagen	2.87	2.32	2.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NAKA KindlyMD	N/A
TOI Oncology Institute	36.86%
VMD Viemed Healthcare	74.24%
XGN Exagen	75.25%

Insider Ownership

Company	Insider Ownership
NAKA KindlyMD	50.50%
TOI Oncology Institute	8.50%
VMD Viemed Healthcare	20.00%
XGN Exagen	12.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NAKA KindlyMD	N/A	6.03 million	2.99 million	N/A
TOI Oncology Institute	660	89.23 million	81.65 million	Not Optionable
VMD Viemed Healthcare	1,179	39.52 million	31.62 million	Not Optionable
XGN Exagen	220	21.30 million	18.62 million	Optionable

NAKA, TOI, VMD, and XGN Headlines

Recent News About These Companies

Exagen (NASDAQ:XGN) versus Varex Imaging (NASDAQ:VREX) Head to Head Review

July 18 at 2:59 AM | americanbankingnews.com

Exagen Inc. Appoints Chas McKhann to Board of Directors

July 17, 2025 | globenewswire.com

Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

July 15, 2025 | globenewswire.com

Exagen Insider Ups Holding During Year

June 29, 2025 | finance.yahoo.com

2025-06-23 | Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics | NDAQ:XGN | Press Release - Stockhouse

June 24, 2025 | stockhouse.com

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

June 23, 2025 | globenewswire.com

Exagen announces resale of up to 1.15M shares

June 20, 2025 | msn.com

Exagen Inc. Holds 2025 Annual Stockholder Meeting

June 11, 2025 | tipranks.com

Exagen Inc. (NASDAQ:XGN) Q1 2025 Earnings Call Transcript

May 11, 2025 | insidermonkey.com

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

May 9, 2025 | finance.yahoo.com

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

May 9, 2025 | globenewswire.com

Exagen Inc. Prices Public Offering of Common Stock

May 8, 2025 | globenewswire.com

KeyBanc maintains Exagen stock at Sector Weight

May 7, 2025 | investing.com

KeyBanc maintains Exagen stock at Sector Weight

May 7, 2025 | investing.com

Exagen Inc. Announces Proposed Public Offering of Common Stock

May 7, 2025 | globenewswire.com

Earnings call transcript: Exagen Inc. Q1 2025 revenue beats forecasts, stock dips

May 6, 2025 | uk.investing.com

Exagen Inc. Reports Record Revenue Amid Strategic Growth

May 5, 2025 | tipranks.com

Exagen Inc. Earnings Call Highlights Record Growth

May 5, 2025 | tipranks.com

Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript

May 5, 2025 | seekingalpha.com

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

May 5, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAKA, TOI, VMD, and XGN Company Descriptions

KindlyMD NASDAQ:NAKA

$11.02 -0.41 (-3.59%)

As of 07/18/2025 04:00 PM Eastern

Kindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.

Oncology Institute NASDAQ:TOI

$3.50 -0.15 (-4.11%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.62 +0.12 (+3.29%)

As of 06:10 AM Eastern

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Viemed Healthcare NASDAQ:VMD

$6.49 -0.18 (-2.70%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$6.49 0.00 (0.00%)

As of 07/18/2025 04:01 PM Eastern

Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

Exagen NASDAQ:XGN

$7.00 -0.18 (-2.51%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.02 +0.01 (+0.21%)

As of 07/18/2025 04:04 PM Eastern

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time